A clear answer to one of the most-asked questions about compounded GLP-1 medications — and what “not FDA-approved” does and doesn't mean.
Compounded tirzepatide is not FDA-approved. The FDA approves finished drug products; for tirzepatide those are Mounjaro® (type 2 diabetes) and Zepbound® (chronic weight management), both made by Eli Lilly and Company. Compounded tirzepatide is prepared by a licensed compounding pharmacy against an individual prescription and is not reviewed or approved by the FDA as a finished product. This applies to every compounded GLP-1 provider.
Because compounded products don't carry FDA finished-product approval, manufacturing and testing oversight differ from brand-name drugs. That's why pharmacy transparency matters: which 503A/503B pharmacies fill the prescription, and whether certificates of analysis are available. See 503A vs 503B and safety & eligibility. Only a licensed clinician can determine whether any tirzepatide product is appropriate for you.
No. Compounded tirzepatide is not FDA-approved. The FDA-approved tirzepatide products are Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), both made by Eli Lilly. Compounded preparations are made by pharmacies per individual prescription and are not FDA-approved as finished products.
Compounded medications are permitted under federal law when prepared by appropriately licensed 503A or 503B pharmacies for a valid prescription, subject to FDA and state rules. Legal status and enforcement can change; eligibility is determined by a licensed clinician.
Compounded tirzepatide is intended to contain the same active ingredient as the brand products, but it has not gone through FDA finished-product approval, so testing and manufacturing oversight differ. Discuss pharmacy quality and certificates of analysis with the provider.